JP2004523538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523538A5 JP2004523538A5 JP2002562389A JP2002562389A JP2004523538A5 JP 2004523538 A5 JP2004523538 A5 JP 2004523538A5 JP 2002562389 A JP2002562389 A JP 2002562389A JP 2002562389 A JP2002562389 A JP 2002562389A JP 2004523538 A5 JP2004523538 A5 JP 2004523538A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- therapeutic agent
- agent according
- ischemic stroke
- humans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0103174.9A GB0103174D0 (en) | 2001-02-08 | 2001-02-08 | Novel method of treatment |
| GB0103174.9 | 2001-02-08 | ||
| PCT/GB2002/000551 WO2002062383A2 (en) | 2001-02-08 | 2002-02-08 | Antagonists of myelin-associated glycoprotein and their use in the treatment and/or prevention of neurological diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008137916A Division JP2008291031A (ja) | 2001-02-08 | 2008-05-27 | 新規治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523538A JP2004523538A (ja) | 2004-08-05 |
| JP2004523538A5 true JP2004523538A5 (enExample) | 2005-12-22 |
| JP5005156B2 JP5005156B2 (ja) | 2012-08-22 |
Family
ID=9908386
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002562389A Expired - Fee Related JP5005156B2 (ja) | 2001-02-08 | 2002-02-08 | 新規治療方法 |
| JP2008137916A Ceased JP2008291031A (ja) | 2001-02-08 | 2008-05-27 | 新規治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008137916A Ceased JP2008291031A (ja) | 2001-02-08 | 2008-05-27 | 新規治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20040170627A1 (enExample) |
| EP (2) | EP1645285A3 (enExample) |
| JP (2) | JP5005156B2 (enExample) |
| AT (1) | ATE314861T1 (enExample) |
| AU (1) | AU2002229928A1 (enExample) |
| CY (1) | CY1105549T1 (enExample) |
| DE (1) | DE60208534T2 (enExample) |
| DK (1) | DK1357941T3 (enExample) |
| ES (1) | ES2254655T3 (enExample) |
| GB (1) | GB0103174D0 (enExample) |
| WO (1) | WO2002062383A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0103174D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Plc | Novel method of treatment |
| US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
| AR040778A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| GB0306309D0 (en) * | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
| US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
| EP3211084B1 (en) * | 2003-05-16 | 2019-03-27 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
| WO2005060368A2 (en) * | 2003-12-10 | 2005-07-07 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use |
| JP5189985B2 (ja) | 2005-09-26 | 2013-04-24 | アコーダ セラピューティクス、インク． | コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法 |
| US20100189721A1 (en) * | 2007-07-06 | 2010-07-29 | Smithkline Beecham Corporation | Antibody formulations |
| US8974782B2 (en) | 2011-02-07 | 2015-03-10 | Glaxo Group Limited | Treatment of stroke comprising anti-MAG antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5250414A (en) * | 1988-11-04 | 1993-10-05 | Erziehungsdirektion Of The Canton Zurich | Diagnostic methods using neurite growth regulatory factors |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US5182107A (en) * | 1989-09-07 | 1993-01-26 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates |
| US5527527A (en) * | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| GB9403250D0 (en) * | 1994-02-21 | 1994-04-13 | Univ Mcgill | Therapeutic use of myelin-associated glycoprotein (mag) |
| US6576607B1 (en) * | 1995-04-19 | 2003-06-10 | Acorda Therapeutics | Methods using CNS neurite outgrowth modulators |
| US5792743A (en) * | 1995-04-19 | 1998-08-11 | Acorda Therapeutics | Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule |
| US5932542A (en) * | 1995-06-27 | 1999-08-03 | Research Foundation Of Cuny, Hunter College | Composition and methods using myelin-associated glycoprotein (MAG) and inhibitors thereof |
| DK1047449T3 (da) * | 1997-10-28 | 2004-01-26 | Univ British Columbia | Immunologiske præparater og anvendelse deraf til forbigående ændring af myelin i centralnervesystemet hos pattedyr for at fremme neuronal regenerering |
| WO1999025379A1 (en) * | 1997-11-14 | 1999-05-27 | Euro-Celtique, S.A. | Modified antibodies with enhanced ability to elicit an anti-idiotype response |
| WO1999053945A1 (en) * | 1998-04-16 | 1999-10-28 | Samuel David | Neuron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| GB0103174D0 (en) * | 2001-02-08 | 2001-03-28 | Smithkline Beecham Plc | Novel method of treatment |
| US20040002790A1 (en) * | 2002-06-28 | 2004-01-01 | Paul Senn | Sensitive devices and sensitive applications |
| AR040778A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| GB0306309D0 (en) * | 2003-03-19 | 2003-04-23 | Glaxo Group Ltd | Method of treatment |
-
2001
- 2001-02-08 GB GBGB0103174.9A patent/GB0103174D0/en not_active Ceased
-
2002
- 2002-02-08 AT AT02711034T patent/ATE314861T1/de active
- 2002-02-08 WO PCT/GB2002/000551 patent/WO2002062383A2/en not_active Ceased
- 2002-02-08 DE DE60208534T patent/DE60208534T2/de not_active Expired - Lifetime
- 2002-02-08 DK DK02711034T patent/DK1357941T3/da active
- 2002-02-08 JP JP2002562389A patent/JP5005156B2/ja not_active Expired - Fee Related
- 2002-02-08 EP EP05077130A patent/EP1645285A3/en not_active Withdrawn
- 2002-02-08 EP EP02711034A patent/EP1357941B1/en not_active Expired - Lifetime
- 2002-02-08 AU AU2002229928A patent/AU2002229928A1/en not_active Abandoned
- 2002-02-08 ES ES02711034T patent/ES2254655T3/es not_active Expired - Lifetime
- 2002-02-08 US US10/467,253 patent/US20040170627A1/en not_active Abandoned
-
2006
- 2006-02-01 CY CY20061100125T patent/CY1105549T1/el unknown
-
2007
- 2007-05-09 US US11/746,355 patent/US20080014195A1/en not_active Abandoned
-
2008
- 2008-05-27 JP JP2008137916A patent/JP2008291031A/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518742A5 (enExample) | ||
| JP2022031635A5 (enExample) | ||
| TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
| ATE471946T1 (de) | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| JP2007051159A5 (enExample) | ||
| ATE437655T1 (de) | Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper | |
| DE05075555T1 (de) | Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern | |
| ATE364699T1 (de) | Humanisierte antikörper gegen humanes gp39, zusammensetzungen die diese enthalten und deren therapeutische verwendungen | |
| DE60141043D1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| ATE557042T1 (de) | Anti-myostatin-antikörper | |
| EA201300022A1 (ru) | Терапевтическое человеческое моноклональное антитело против il-1r1 | |
| PE20160999A1 (es) | Metodos para administrar anticuerpos anti-tnf-alfa | |
| WO2010055366A3 (en) | Anti-human il-21 monoclonal antibodies | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| IL134888A0 (en) | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING THEM AND THERAPEUTIC USE THEREOF | |
| ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
| JP2006514116A5 (enExample) | ||
| WO2003054018A3 (en) | Anti-tirc7 antibodies in therapy of inflammatory diseases | |
| JP2018529672A5 (enExample) | ||
| JP2020508074A5 (enExample) | ||
| JP2004508415A5 (enExample) | ||
| TR200103432T2 (tr) | Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı. | |
| ATE457318T1 (de) | Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper |